Status:
COMPLETED
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
Lead Sponsor:
Ipsen
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from comp...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Completed the 2-79-52030-207 study and received 12 injections of lanreotide Autogel 120 mg, regardless of efficacy at the end of this period.
- Subject or in case of subject's death next of kin having given their written informed consent prior to collection of the data by the sponsor (if locally required)
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01471405
Start Date
January 1 2012
End Date
August 1 2013
Last Update
January 11 2019
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
III. Interní klinika Karlova Univerzita
Prague, Czechia
2
CHU de Rouen
Bois-Guillaume, France, 76230
3
Groupement hôspitalier est Federation d'endocrinologie.
Bron, France
4
CHU Michallon
Grenoble, France